期刊
IMMUNOTHERAPY
卷 13, 期 1, 页码 -出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0225
关键词
biologic DMARD; IL-17A antagonist; ixekizumab; psoriasis; psoriatic arthritis; spondyloarthritis
类别
Psoriatic arthritis (PsA) is a chronic rheumatic disorder with various phenotypic features. IL-17 plays a critical role in the onset of PsA, and the monoclonal antibody Ixekizumab, targeting IL-17A, has shown promising efficacy and safety in PsA treatment.
Psoriatic arthritis (PsA) is a heterogeneous chronic rheumatic disorder with numerous phenotypic facets. A better in deep understanding of the pathophysiologic mechanisms leading to psoriasis and PsA has contributed to the introduction of novel therapeutic agents. IL-17 is at the heart and a critical factor in the onset of PsA. Ixekizumab, a high-affinity monoclonal antibody against IL-17 A, has been approved by the US FDA in March 2016 for baseline psoriasis and Dec 2017 for PsA; by the EMA in April 2016 and January 2018, respectively. This article reviews the published data relating to ixekizumab efficacy and safety in the PsA treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据